Q3 Earnings Forecast for OKYO Pharma Issued By HC Wainwright

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) – Equities researchers at HC Wainwright issued their Q3 2027 EPS estimates for OKYO Pharma in a research note issued to investors on Monday, July 13th. HC Wainwright analyst Y. Chen forecasts that the company will earn ($0.03) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for OKYO Pharma’s current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for OKYO Pharma’s Q4 2027 earnings at ($0.03) EPS, FY2027 earnings at ($0.13) EPS, Q1 2028 earnings at ($0.03) EPS, Q2 2028 earnings at ($0.04) EPS, Q3 2028 earnings at ($0.04) EPS, Q4 2028 earnings at ($0.04) EPS and FY2028 earnings at ($0.15) EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $5.67.

OKYO Pharma Price Performance

OKYO stock opened at $1.55 on Tuesday. The firm has a 50 day moving average of $1.61 and a two-hundred day moving average of $1.77. OKYO Pharma has a 12 month low of $1.42 and a 12 month high of $3.35.

Institutional Investors Weigh In On OKYO Pharma

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in shares of OKYO Pharma during the fourth quarter valued at approximately $36,000. Renaissance Technologies LLC increased its holdings in OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after buying an additional 96,800 shares during the period. Finally, Citadel Advisors LLC bought a new stake in OKYO Pharma in the 3rd quarter valued at $31,000. 2.97% of the stock is owned by institutional investors and hedge funds.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.